Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CTR002
MIFTS: 60

Cataract

Categories: Eye diseases, Fetal diseases, Genetic diseases, Metabolic diseases, Nephrological diseases, Neuronal diseases, Oral diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Cataract

About this section

MalaCards integrated aliases for Cataract:

Name: Cataract 12 74 36 29 54 6 42 43 15 39 17
Cataracts 15 62

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Metabolic diseases Fetal diseases
Anatomical: Eye diseases Nephrological diseases Neuronal diseases Oral diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:83
KEGG 36 H01202
ICD9CM 34 366.8
MeSH 43 D002386
UMLS 71 C0029531
Sources

Summaries for Cataract

About this section
KEGG : 36 Cataracts can be defined as any opacity of the crystalline lens, often associated with breakdown of the lens microarchitecture, possibly including vacuole formation and disarray of lens cells, which can cause large fluctuations in density resulting in light scattering. In addition, light scattering and opacity will occur if there is a significant amount of high molecular weight protein aggregates. Cataracts can be classified by the age at onset: a congenital or infantile cataract presents within the first year of life; a juvenile cataract presents within the first decade of life; a presenile cataract presents before the age of about 45 years, and senile or age-related cataract after that. Congenital cataracts are a major cause of induced blindness in children, and inherited cataracts are the major cause of congenital cataracts. Inherited congenital cataracts have been associated with mutations in specific genes, including those of crystallins, gap junction proteins, membrane transport and channel proteins, the cytoskeleton, and growth and transcription factors. Inherited congenital cataracts may be inherited as autosomal dominant (most frequent), autosomal recessive, or X-linked traits.

MalaCards based summary : Cataract, also known as cataracts, is related to cataract 1, multiple types and cataract 9, multiple types. An important gene associated with Cataract is LIM2 (Lens Intrinsic Membrane Protein 2), and among its related pathways/superpathways is Protein processing in endoplasmic reticulum. The drugs Tropicamide and Polymyxin B have been mentioned in the context of this disorder. Affiliated tissues include Eye, endothelial and testes, and related phenotype is vision/eye.

Disease Ontology : 12 A lens disease characterized by clouding of the lens inside the eye which leads to a decrease in vision.

MedlinePlus : 42 A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision Frequent prescription changes in your eye wear Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute

PubMed Health : 62 About cataracts: A cataract is an eye condition in which the lens of the eye becomes cloudy. This causes vision to worsen, making it especially difficult to see fine details clearly. Some people’s vision is only slightly affected, whereas others might lose their eyesight very quickly. How it progresses will depend on things like the exact type of cataract. The word “cataract” comes from the Greek word for “waterfall” because in the past it was believed that the blurring was caused by a fluid in the eye. Cataracts mostly affect people over 50, and the risk increases with age: About 20 out of 100 people between the ages of 65 and 74 have a cataract. And more than 50 out of 100 people over the age of 74 are affected. Cataracts are the main cause of blindness in developing countries. The number of people who go blind from cataracts is considerably lower in industrialized countries due to the availability of effective surgery. Cataract surgery involves removing the cloudy eye lens and replacing it with an artificial lens. It is one of the most common surgical procedures performed in Germany, where about 800,000 people have cataract surgery every year.

Wikipedia : 74 A cataract is a clouding of the lens in the eye which leads to a decrease in vision. Cataracts often... more...

Sources

Related Diseases for Cataract

About this section

Diseases in the Cataract family:

Cataract 32, Multiple Types Cataract 7
Cataract 8, Multiple Types Cataract 4, Multiple Types
Cataract 29 Cataract 42
Cataract 20, Multiple Types Cataract 1, Multiple Types
Cataract 30, Multiple Types Cataract 41
Cataract 6, Multiple Types Cataract 5, Multiple Types
Cataract 46, Juvenile-Onset Cataract 40
Cataract 10, Multiple Types Cataract 24
Cataract 3, Multiple Types Cataract 14, Multiple Types
Cataract 9, Multiple Types Cataract 2, Multiple Types
Cataract 31, Multiple Types Cataract 25
Cataract 26, Multiple Types Cataract 27
Cataract 28 Cataract 35
Cataract 22, Multiple Types Cataract 18
Cataract 21, Multiple Types Cataract 23, Multiple Types
Cataract 11, Multiple Types Cataract 33, Multiple Types
Cataract 17, Multiple Types Cataract 12, Multiple Types
Cataract 47 Cataract 34, Multiple Types
Cataract 16, Multiple Types Cataract 36
Cataract 37 Cataract 38
Cataract 39, Multiple Types Cataract 15, Multiple Types
Cataract 19, Multiple Types Cataract 43
Cataract 44 Cataract 45
Cataract 48 Cataract 30
Cataract 33 Cataract Congenital Autosomal Dominant
Cataract, Total Congenital

Diseases related to Cataract via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1649)
# Related Disease Score Top Affiliating Genes
1 cataract 1, multiple types 35.4 GJA8 GJA3 CRYAA
2 cataract 9, multiple types 35.3 GJA8 CRYAA
3 cataract 30, multiple types 35.3 GJA8 GJA3 CRYGD CRYGC
4 cataract 24 35.2 CTAA2 CRYBB3 CRYAA
5 cataract 6, multiple types 35.2 CRYBA1 CRYAA
6 cataract microcornea syndrome 35.2 GJA8 CRYGD CRYGC CRYAA
7 cataract 16, multiple types 35.2 CRYBA1 CRYAA
8 cataract 11, multiple types 35.2 CRYBA1 CRYAA
9 cataract 44 35.2 LIM2 GJA8 CRYAA
10 cataract 32, multiple types 35.1 CRYBA1 CRYAA
11 posterior polar cataract 35.1 GJA3 CRYGS CRYGD CRYBA1 CRYAA
12 cataract 14, multiple types 35.1 GJA8 GJA3
13 cataract 31, multiple types 35.1 CRYBA1 CRYAA
14 cerulean cataract 35.0 CTRCT37 CRYGD
15 cataract 29 35.0 CTRCT29 CRYGD
16 early-onset nuclear cataract 34.9 GJA8 GJA3 CRYGD CRYGC CRYBB3 CRYBA1
17 nuclear senile cataract 34.9 CRYGS CRYGD
18 cataract 28 34.9 CTRCT28 CRYAA
19 mature cataract 34.8 CRYGS CRYAA
20 diabetic cataract 34.7 CRYGS CRYAA
21 early-onset sutural cataract 34.5 GJA8 CRYGS CRYBA1
22 early-onset posterior polar cataract 34.5 GJA3 CRYBA1
23 nance-horan syndrome 34.5 CRYBB3 CRYBA1 CRYAA
24 early-onset lamellar cataract 34.4 CRYGS CRYGD CRYGC CRYBA1 CRYAA
25 galactokinase deficiency 34.3 CRYGS CRYAA
26 amblyopia 33.6 GJA3 CRYGS CRYBB3 CRYAA
27 hallermann-streiff syndrome 33.3 GJA3 CRYAA
28 rare disorder with lens opacification 33.0 RHO LIM2 IARS2
29 gyrate atrophy of choroid and retina 32.9 RHO CRYAA
30 lens disease 32.5 RHO GJA8 GJA3 CRYGS CRYBA1 CRYAA
31 leber congenital amaurosis 2 32.1 RHO CRYAA
32 presbyopia 31.7 CRYGS CRYAA
33 leukocoria 31.3 CRYBA1 CRYAA
34 sclerocornea 30.9 GJA8 CRYAA
35 congenital nystagmus 30.6 GJA8 CRYAA
36 vitreous disease 30.4 RHO CRYAA
37 hyperferritinemia with or without cataract 12.7
38 cataract 4, multiple types 12.7
39 cataract 21, multiple types 12.7
40 cataract 3, multiple types 12.6
41 cataract 22, multiple types 12.6
42 cataract 2, multiple types 12.6
43 cataract 17, multiple types 12.6
44 cataract 40 12.6
45 cataract 5, multiple types 12.6
46 cataract 10, multiple types 12.6
47 cataract 18 12.6
48 cataract 23, multiple types 12.6
49 cataract 34, multiple types 12.6
50 cataract 8, multiple types 12.6

Graphical network of the top 20 diseases related to Cataract:



Diseases related to Cataract
Sources

Symptoms & Phenotypes for Cataract

About this section

MGI Mouse Phenotypes related to Cataract:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.28 CRYBA1 CRYGC CRYGD CRYGS GJA3 GJA8
Sources

Drugs & Therapeutics for Cataract

About this section

PubMed Health treatment related to Cataract: 62

Some people can compensate for the vision loss, temporarily or even in the longer term, by wearing glasses or contact lenses . There are no medications for the treatment of cataracts . The only effective treatment is surgery . Cataract surgery involves removing the cloudy lens and replacing it with a new, artificial lens. The lens capsule – an elastic membrane surrounding the lens of the eye – is left in the eye during surgery. Only the inner core and the outer cortex of the lens are broken up into small pieces using ultrasound. The pieces are then sucked out of the eye through a small cut. This procedure, called phacoemulsification , is the standard technique in Germany and some other countries. Once the lens has been removed, an artificial lens is implanted into the lens capsule. Whether and when surgery is an appropriate treatment option is very much a personal decision. The extent to which vision loss is affecting someone’s life will play a very important role. Another factor to consider is the presence of other (eye ) conditions, which could affect the outcome of cataract surgery .

Drugs for Cataract (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 449)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tropicamide Approved, Investigational Phase 4 1508-75-4 5593
2
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
3
Cefazolin Approved Phase 4 25953-19-9 656510 33255
4
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
5
Alogliptin Approved Phase 4 850649-61-5 11450633
6
Besifloxacin Approved Phase 4 141388-76-3
7
Dinoprostone Approved Phase 4 363-24-6 5280360
8
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
9
Povidone Approved Phase 4 9003-39-8
10
Difluprednate Approved Phase 4 23674-86-4 443936
11
Fluprednisolone Approved Phase 4 53-34-9
12
Bromfenac Approved Phase 4 91714-94-2 60726
13
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
14
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
15
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
16
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
17
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
18
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
19
Dalteparin Approved Phase 4 9005-49-6
20
Enoxaparin Approved Phase 4 9005-49-6 772
21 Orange Approved Phase 4
22
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
23
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
24
Azithromycin Approved Phase 4 83905-01-5 55185 447043
25
Homatropine Approved Phase 4 87-00-3
26
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
27
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
28
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
29
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
30
Ethanol Approved Phase 4 64-17-5 702
31
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
32
Cocaine Approved, Illicit Phase 4 50-36-2 5760 446220
33
Budesonide Approved Phase 4 51333-22-3 63006 5281004
34
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
35
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
36
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
37
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
38
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
39
Polyestradiol phosphate Approved Phase 4 28014-46-2
40
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
41
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
42
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
43
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
44
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
45
Brinzolamide Approved Phase 4 138890-62-7 68844
46
Timolol Approved Phase 4 26839-75-8 33624 5478
47
Empagliflozin Approved Phase 4 864070-44-0
48
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
49
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
50
Travoprost Approved Phase 4 157283-68-6 5282226

Interventional clinical trials:

(show top 50) (show all 1507)
# Name Status NCT ID Phase Drugs
1 Relevance of Eye Dominance in the Selection of Patients Suitable for Treatment With Monovision After Cataract Surgery Unknown status NCT01382641 Phase 4
2 Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia Unknown status NCT01554761 Phase 4
3 A Study to Assess the Clinical Outcomes of Surgical Phaco Segmentation Techniques in Patients Undergoing Cataract Surgery Unknown status NCT02843594 Phase 4
4 Clinical Investigation of the Modified Rayner Monofocal Aspheric 600C (With Axis Marks) Intraocular Lens Unknown status NCT02378636 Phase 4
5 Efficacy of Subtenon Anesthesia With Olive Tipped Cannula: a Randomized Controlled Trial Unknown status NCT01019018 Phase 4
6 AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL Unknown status NCT01278420 Phase 4
7 Comparative Study of the Safety and Effectiveness Between Off-Label Subconjunctival Bevacizumab and Mitomycin C in Glaucoma Filtering Surgery. Unknown status NCT00468429 Phase 4 Subconjunctival Bevacizumab
8 The Effect of Pretreated Gabapentin on Hyeralgesia Occurring in the Second Operation in Staged Bilateral Cataract Surgery Unknown status NCT02127853 Phase 4 gabapentin;placebo
9 Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Unknown status NCT01193504 Phase 4 Pred Forte;Lotemax
10 Clinical Evaluation of Toric Intraocular Lens Made by Aurolab Unknown status NCT01396616 Phase 4
11 Quantitative Comparison of the Efficacy of Subtenon 20-mg Triamcinolone Injection With 0.1% Dexamethasone Eye Drop in Controlling Intraocular Inflammation After Phacoemulsification Unknown status NCT01801774 Phase 4 Subtenon 20-mg triamcinolone injection;Placebo
12 Effect of Anti-inflammatory Topical Prednisolone Acetate 1%, Nepafenac of 0.1% and Ketorolac Tromethamine 0.4% in Intra-operative Mydriasis in Facetectomies Unknown status NCT00865540 Phase 4 prednisolone acetate 1%;ketorolac tromethamine 0.4%;nepafenac 0.1%;methylcellulose 0.5%
13 Combined Phacoemulsification and Glaucoma Implant Surgery Versus Combined Phacoemulsification and Trabeculectomy: A Randomized Controlled Trial Unknown status NCT00273221 Phase 4
14 Assessment in Early Changes in the Parameters of Optical Coherence Tomography (OCT Spectral Domain) in Patients With Subfoveal Neovascular Membranes Related to Age After Treatment With a Single Intravitreal Injection of Lucentis. Unknown status NCT01669447 Phase 4
15 Heavy Bupivacaine Versus Plain Bupivacaine in Peribulbar Block Unknown status NCT03312959 Phase 4 hyperbaric bupvacaine in Peribulbar block;isobaric bupvacaine in Peribulbar block
16 A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperative Topical Prostaglandin Unknown status NCT02873806 Phase 4 Topical travoprost;Tobramycin;Dexamethasone
17 Cefazolin-Lidocaine Solution for Reducing Pain Associated With Subconjunctival Antibiotic Prophylaxis in Vitreo-Retinal Surgery Unknown status NCT02324166 Phase 4 Cefazolin;Lidocaine
18 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
19 Pilot Study of Prevention Myopia in Children With Low Concentration of Atropine Unknown status NCT00541177 Phase 4 atropine;tropicamide
20 EFFECTS OF IMMEDIATE ARGON LASER PERIPHERAL IRIDOPLASTY Versus CONVENTIONAL SYSTEMIC MEDICAL THERAPY ON OPTIC NERVE HEAD STRUCTURE AND FUNCTION OF ACUTE PRIMARY ANGLE CLOSURE EYES Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
21 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
22 A Phase IV, Multicenter, Randomized, Active Comparator Controlled Study of the Addition of Pioglitazone Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Alogliptin Unknown status NCT02426294 Phase 4 Pioglitazone;Glimepiride
23 Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery Completed NCT01383057 Phase 4
24 Laser Cataract Surgery With the Femtosecond Laser Technology Completed NCT01382823 Phase 4
25 Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric Intraocular Lens (IOL): Postmarket Evaluation Completed NCT00818116 Phase 4
26 Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions Completed NCT01298973 Phase 4 Viscoat;Saline
27 Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial Completed NCT01279031 Phase 4
28 Evaluation of the Acrysof Toric Model SN60T3 Intraocular Lens in Patients With Predicted Residual Corneal Astigmatism Between 0.75 and 1.03 Diopters (D) Completed NCT00732030 Phase 4
29 Selection of Aspheric Diffractive Multifocal IOLS Based on Corneal Wavefront Completed NCT00999492 Phase 4
30 Clinical Outcomes With AcrySof ReSTOR Aspheric Apodized Diffractive Intraocular Lens (IOL) in One Eye and a Contralateral Monofocal IOL or Phakic Eye Completed NCT00731640 Phase 4
31 A Prospective, Randomized Single-Masked Clinical Trial Comparing OCT and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care Completed NCT00698724 Phase 4 Xibrom, and Optive;Xibrom and Pred Forte
32 Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery Completed NCT00758199 Phase 4 Bromfenac;Moxifloxacin hydrochloride;Prednisolone Acetate
33 A Randomized, Masked Multi-center Safety & Efficacy Study of the Effects of Preoperative & Postoperative Cataract Surgery Use of Difluprednate Ophthalmic Emulsion, 0.05% Compared to Prednisolone Acetate Ophthalmic Suspension 1% on Visual Acuity & Corneal Edema. Completed NCT01244334 Phase 4 Difluprednate ophthalmic emulsion 0.05%;Prednisolone acetate 1%
34 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification Completed NCT01296191 Phase 4 Moxifloxacin;besifloxacin
35 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail, Xibrom and Nevanac in Patients Undergoing Phacoemulsification Completed NCT01021761 Phase 4 Ketorolac Tromethamine;Bromfenac;nepafenac
36 A Comparison of Peak Aqueous Penetration of Acuvail, Xibrom, and Nevanac in Patients Undergoing Phacoemulsification Completed NCT01001806 Phase 4 Ketorolac Tromethamine 0.45%;bromfenac 0.09%;nepafenac 0.1%
37 Effect of Nepafenac on Post-operative Cystoid Macular Edema Following Uncomplicated Cataract Surgery Completed NCT00494494 Phase 4 Standard Care;nepafenac
38 Clinical Outcomes After Bilateral Implantation of ZEISS AT LISA TRI AND TRI TORIC IOL Completed NCT02770924 Phase 4
39 A Randomised Trial of Torsional Ultrasound Versus Longitudinal Ultrasound During Phacoemulsification of Age-related Cataracts: Comparison of Intra-operative Performance and Impact on Post-operative Endothelium Integrity Completed NCT01010490 Phase 4
40 Comparison of the Quality of Vision Provided by AMO Tecnis Z9000 Three-piece Silicone Posterior Chamber Intraocular Lens and Alcon Laboratories MA60 Acrysof Three-piece Acrylic Posterior Chamber Intraocular Lens Completed NCT00348270 Phase 4
41 Indomethacin Eyedrops Compared With Ketorolac Eyedrops for Ocular Inflammation Following Cataract Surgery Completed NCT00904904 Phase 4 Indomethacin ophthalmic solution;Ketorolac Ophthalmic Solution
42 Monocular Study to Evaluate the Safety and Effectiveness of the Akreos™ Toric IOL When Used to Correct Primary Aphakia With the Reduction of Astigmatism Completed NCT00825513 Phase 4
43 Parallel-group Study of Ocular Penetration of Peri-operative Topically Administered Fluoroquinolones With Cataract Surgery Completed NCT00924729 Phase 4 Moxifloxacin 0.5% ophthalmic solution;Besifloxacin 0.6% ophthalmic suspension
44 Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients Completed NCT01859702 Phase 4 Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution
45 Therapeutic Variables in Cataract Surgery Completed NCT00407017 Phase 4 Gatifloxacin;Ketorolac LS;Pred Forte;Moxifloxacin;Nepafenac;EconoPred Plus
46 Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery Completed NCT00348582 Phase 4 Ketorolac, Nepafenac
47 A Masked Comparison of Acular LS Plus Steroid Versus Steroid Alone for the Prevention of Macular Leakage in Cataract Patients Completed NCT00348244 Phase 4 Ketorolac, Prednisolone Acetate
48 DisCoVisc Versus Competitor Completed NCT00712244 Phase 4
49 Use of Toric Intraocular Lens to Neutralize Keratometric Astigmatism Completed NCT00925886 Phase 4
50 Visual Function With Bilateral AcrySof® ReSTOR® Aspheric SN6AD1 Completed NCT00710931 Phase 4

Search NIH Clinical Center for Cataract

Cochrane evidence based reviews: cataract

Sources

Genetic Tests for Cataract

About this section

Genetic tests related to Cataract:

# Genetic test Affiliating Genes
1 Cataract 29
Sources

Anatomical Context for Cataract

About this section

MalaCards organs/tissues related to Cataract:

40
Eye, Endothelial, Testes, Bone, Bone Marrow, Brain, Retina
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cataract:
# Tissue Anatomical CompartmentCell Relevance
1 Eye Lens Affected by disease
Sources

Publications for Cataract

About this section

Articles related to Cataract:

(show top 50) (show all 37952)
# Title Authors PMID Year
1
Peri-operative considerations for sedation-analgesia during cataract surgery: a narrative review. 61 42
31535721 2019
2
Quantitative assessment of early Type 2 diabetic cataracts using T1,T2-mapping techniques. 61 42
31398062 2019
3
Systematic Review and Meta-Analysis of Comparing Phacoemulsification Combined with goniosynechialysis to other mainstream procedures in treating patients with angle-closure glaucoma. 42
31626152 2019
4
Cerebrotendinous xanthomatosis (CTX): an association of pulverulent cataracts and pseudo-dominant developmental delay in a family with a splice site mutation in CYP27A1--a case report. 54 61
20450308 2010
5
In vivo lens deficiency of the R49C alphaA-crystallin mutant. 54 61
20188090 2010
6
A novel human CRYGD mutation in a juvenile autosomal dominant cataract. 54 61
20508808 2010
7
Hyperferritinaemia-cataract syndrome: worldwide mutations and phenotype of an increasingly diagnosed genetic disorder. 54 61
20511138 2010
8
Oxidative stress markers in patients with primary open-angle glaucoma. 54 61
20373896 2010
9
Later retinal degeneration following childhood surgical aphakia in a family with recessive CRYAB mutation (p.R56W). 54 61
20141356 2010
10
A novel mutation in the major intrinsic protein (MIP) associated with autosomal dominant congenital cataracts in a Chinese family. 54 61
20361015 2010
11
[Progress in pathogenic genes and their functions of congenital cataract]. 54 61
20450675 2010
12
HTS-Compatible Patient-Derived Cell-Based Assay to Identify Small Molecule Modulators of Aberrant Splicing in Myotonic Dystrophy Type 1. 54 61
20502647 2010
13
Megakaryocyte and platelet abnormalities in a patient with a W33C mutation in the conserved SH3-like domain of myosin heavy chain IIA. 54 61
19967157 2009
14
A novel GJA8 mutation (p.I31T) causing autosomal dominant congenital cataract in a Chinese family. 54 61
20019893 2009
15
[Hereditary hyperferritinemia cataract syndrome--the first family in Germany]. 54 61
19994473 2009
16
Glucose-6-phosphate dehydrogenase (G6PD) deficiency and senile cataract in a Sardinian male population, Italy. 54 61
19995205 2009
17
A novel mutation (F71L) in alphaA-crystallin with defective chaperone-like function associated with age-related cataract. 54 61
19595763 2009
18
Mutations in MYH9 exons 1, 16, 26, and 30 are infrequently found in Japanese patients with nonsyndromic deafness. 54 61
19645626 2009
19
[Mutation analysis of the PAX6 gene in a family with congenital aniridia and cataract]. 54 61
19806578 2009
20
Synergistic effects of metal ion and the pre-senile cataract-causing G98R alphaA-crystallin: self-aggregation propensities and chaperone activity. 54 61
19862354 2009
21
Effects of alpha-crystallin on lens cell function and cataract pathology. 54 61
19860667 2009
22
Age-related cataracts and Prdx6: correlation between severity of lens opacity, age and the level of Prdx 6 expression. 54 61
19429582 2009
23
A novel gammaD-crystallin mutation causes mild changes in protein properties but leads to congenital coralliform cataract. 54 61
19668596 2009
24
EPHA2 is associated with age-related cortical cataract in mice and humans. 54 61
19649315 2009
25
Founder heterozygous P23T CRYGD mutation associated with cerulean (and coralliform) cataract in 2 Saudi families. 54 61
19633732 2009
26
Antioxidant status modifications by topical administration of dorzolamide in primary open-angle glaucoma. 54 61
19551670 2009
27
Bilateral cataract in a subject carrying a C to A transition in the L ferritin promoter region. 54 61
19254706 2009
28
An alphaA-crystallin gene mutation, Arg12Cys, causing inherited cataract-microcornea exhibits an altered heat-shock response. 54 61
19503744 2009
29
Aquaporins: translating bench research to human disease. 54 61
19448080 2009
30
Identification of a novel CRYAB mutation associated with autosomal recessive juvenile cataract in a Saudi family. 54 61
19461931 2009
31
Initiation codon mutation in betaB1-crystallin (CRYBB1) associated with autosomal recessive nuclear pulverulent cataract. 54 61
19461930 2009
32
Deletion of mouse MsrA results in HBO-induced cataract: MsrA repairs mitochondrial cytochrome c. 54 61
19461988 2009
33
Topical use of coenzyme Q10-loaded liposomes coated with trimethyl chitosan: tolerance, precorneal retention and anti-cataract effect. 54 61
19437594 2009
34
Aquaporin water channels in mammals. 54 61
19085041 2009
35
NMR study of the cataract-linked P23T mutant of human gammaD-crystallin shows minor changes in hydrophobic patches that reflect its retrograde solubility. 54 61
19275895 2009
36
Genetics of crystallins: cataract and beyond. 54 61
19007775 2009
37
Removal of Hsf4 leads to cataract development in mice through down-regulation of gamma S-crystallin and Bfsp expression. 54 61
19224648 2009
38
11p Microdeletion including WT1 but not PAX6, presenting with cataract, mental retardation, genital abnormalities and seizures: a case report. 54 61
19222835 2009
39
Mitochondrial function and redox control in the aging eye: role of MsrA and other repair systems in cataract and macular degenerations. 54 61
18588875 2009
40
Oxidative stress markers in aqueous humor of patients with senile cataracts. 54 61
19172468 2009
41
Structural function of MIP/aquaporin 0 in the eye lens; genetic defects lead to congenital inherited cataracts. 54 61
19096783 2009
42
N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population. 54 61
19503764 2009
43
Novel mutation in the gamma-S crystallin gene causing autosomal dominant cataract. 54 61
19262743 2009
44
Disulfide cross-links in the interaction of a cataract-linked alphaA-crystallin mutant with betaB1-crystallin. 54 61
19071118 2009
45
A new locus for congenital cataract, microcornea, microphthalmia, and atypical iris coloboma maps to chromosome 2. 54 61
19004499 2009
46
Autosomal-dominant cerulean cataract in a chinese family associated with gene conversion mutation in beta-B2-crystallin. 54 61
19321936 2009
47
Synergistic effect of osmotic and oxidative stress in slow-developing cataract formation. 54 61
18760274 2008
48
Genistein inhibits aldose reductase activity and high glucose-induced TGF-beta2 expression in human lens epithelial cells. 54 61
18692043 2008
49
A missense mutation in ALDH18A1, encoding Delta1-pyrroline-5-carboxylate synthase (P5CS), causes an autosomal recessive neurocutaneous syndrome. 54 61
18478038 2008
50
Mechanism of insolubilization by a single-point mutation in alphaA-crystallin linked with hereditary human cataracts. 54 61
18700785 2008
Sources

Variations for Cataract

About this section

ClinVar genetic disease variations for Cataract:

6 (show top 50) (show all 136) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IARS2 NM_018060.4(IARS2):c.2726C>T (p.Pro909Leu)SNV Pathogenic 156553 rs587783070 1:220316451-220316451 1:220143109-220143109
2 46;XY;inv(9)(q22.3q34.11)dninversion Pathogenic 267868
3 RHO NM_000539.3(RHO):c.891C>G (p.Ser297Arg)SNV Pathogenic 523376 rs142285818 3:129251570-129251570 3:129532727-129532727
4 LIM2 NM_001161748.2(LIM2):c.388C>T (p.Arg130Cys)SNV Pathogenic 625113 rs1568480054 19:51883831-51883831 19:51380577-51380577
5 WRN NM_000553.5(WRN):c.724+1G>TSNV Likely pathogenic 523380 rs1339616347 8:30925844-30925844 8:31068328-31068328
6 COL5A1 NM_001278074.1(COL5A1):c.608G>T (p.Gly203Val)SNV Likely pathogenic 523328 rs1554781700 9:137593133-137593133 9:134701287-134701287
7 COL18A1 NM_030582.4(COL18A1):c.1469-2A>GSNV Likely pathogenic 373962 rs765919785 21:46897323-46897323 21:45477409-45477409
8 COL18A1 NM_030582.4(COL18A1):c.3979C>T (p.Arg1327Ter)SNV Likely pathogenic 373961 rs1057518802 21:46929468-46929468 21:45509554-45509554
9 HSF4 NM_001040667.3(HSF4):c.1476C>A (p.Pro492=)SNV Conflicting interpretations of pathogenicity 320191 rs367756178 16:67203685-67203685 16:67169782-67169782
10 PITX2 NM_000325.6(PITX2):c.639A>T (p.Ser213=)SNV Conflicting interpretations of pathogenicity 283383 rs141176394 4:111539617-111539617 4:110618461-110618461
11 EPM2A NM_005670.4(EPM2A):c.376A>G (p.Ile126Val)SNV Conflicting interpretations of pathogenicity 167038 rs150452237 6:146007358-146007358 6:145686222-145686222
12 UPF3B NM_080632.2(UPF3B):c.758T>C (p.Ile253Thr)SNV Uncertain significance 284394 rs754982440 X:118975088-118975088 X:119841125-119841125
13 CRYGD NM_006891.4(CRYGD):c.295A>G (p.Arg99Gly)SNV Uncertain significance 333870 rs886055527 2:208986627-208986627 2:208121903-208121903
14 CRYGD NM_006891.4(CRYGD):c.482A>G (p.Asn161Ser)SNV Uncertain significance 333868 rs760434926 2:208986440-208986440 2:208121716-208121716
15 CRYGD NM_006891.3(CRYGD):c.-80A>CSNV Uncertain significance 333880 rs886055528 2:208989277-208989277 2:208124553-208124553
16 XDH NM_000379.4(XDH):c.3647C>A (p.Pro1216His)SNV Uncertain significance 335760 rs143981573 2:31562482-31562482 2:31339616-31339616
17 BFSP2 NM_003571.4(BFSP2):c.422A>C (p.Glu141Ala)SNV Uncertain significance 343407 rs886058009 3:133119349-133119349 3:133400505-133400505
18 BFSP2 NM_003571.4(BFSP2):c.722A>G (p.Tyr241Cys)SNV Uncertain significance 343411 rs886058012 3:133167482-133167482 3:133448638-133448638
19 BFSP2 NM_003571.4(BFSP2):c.*226C>ASNV Uncertain significance 343418 rs574253958 3:133194042-133194042 3:133475198-133475198
20 PITX2 NM_000325.6(PITX2):c.*572T>CSNV Uncertain significance 347289 rs886059003 4:111538709-111538709 4:110617553-110617553
21 PITX2 NM_000325.6(PITX2):c.*373_*375GTT[1]short repeat Uncertain significance 347292 rs886059004 4:111538903-111538905 4:110617747-110617749
22 BFSP2 NM_003571.4(BFSP2):c.865G>A (p.Glu289Lys)SNV Uncertain significance 343412 rs145444931 3:133169282-133169282 3:133450438-133450438
23 BFSP2 NM_003571.4(BFSP2):c.5G>A (p.Ser2Asn)SNV Uncertain significance 343397 rs886058007 3:133118932-133118932 3:133400088-133400088
24 BFSP2 NM_003571.4(BFSP2):c.437G>T (p.Arg146Leu)SNV Uncertain significance 343408 rs148759360 3:133119364-133119364 3:133400520-133400520
25 BFSP2 NM_003571.4(BFSP2):c.701T>C (p.Leu234Pro)SNV Uncertain significance 343410 rs886058011 3:133167461-133167461 3:133448617-133448617
26 BFSP2 NM_003571.4(BFSP2):c.567A>G (p.Lys189=)SNV Uncertain significance 343409 rs886058010 3:133166238-133166238 3:133447394-133447394
27 PITX2 NM_000325.6(PITX2):c.*370G>CSNV Uncertain significance 347293 rs886059005 4:111538911-111538911 4:110617755-110617755
28 PITX2 NM_000325.6(PITX2):c.*264A>CSNV Uncertain significance 347295 rs886059006 4:111539017-111539017 4:110617861-110617861
29 PITX2 NM_000325.6(PITX2):c.412-11deldeletion Uncertain significance 347299 rs886059007 4:111539855-111539855 4:110618699-110618699
30 PITX2 NM_000325.6(PITX2):c.*611A>GSNV Uncertain significance 347288 rs886059002 4:111538670-111538670 4:110617514-110617514
31 PITX2 NM_000325.6(PITX2):c.*522T>CSNV Uncertain significance 347290 rs188349821 4:111538759-111538759 4:110617603-110617603
32 PITX2 NM_000325.6(PITX2):c.*119T>ASNV Uncertain significance 347297 rs765040142 4:111539162-111539162 4:110618006-110618006
33 MIP NM_012064.4(MIP):c.*1777dupduplication Uncertain significance 309861 rs886049688 12:56843286-56843287 12:56449502-56449503
34 MIP NM_012064.4(MIP):c.*1237_*1238dupduplication Uncertain significance 309864 rs111463603 12:56843825-56843826 12:56450041-56450042
35 MIP NM_012064.4(MIP):c.*601G>ASNV Uncertain significance 309874 rs565229690 12:56844463-56844463 12:56450679-56450679
36 HSF4 NM_001040667.3(HSF4):c.1127T>C (p.Leu376Pro)SNV Uncertain significance 320188 rs373962350 16:67202778-67202778 16:67168875-67168875
37 HSF4 NM_001040667.3(HSF4):c.*30deldeletion Uncertain significance 320192 rs756298250 16:67203717-67203717 16:67169814-67169814
38 HSF4 NM_001538.3(HSF4):c.*158_*159dupTTduplication Uncertain significance 320194 rs3215366 16:67203835-67203836 16:67169932-67169933
39 TALDO1 NM_006755.2(TALDO1):c.328A>G (p.Arg110Gly)SNV Uncertain significance 523493 rs766745943 11:759056-759056 11:759056-759056
40 XDH NM_000379.4(XDH):c.1172C>T (p.Pro391Leu)SNV Uncertain significance 598996 rs1558697792 2:31602803-31602803 2:31379937-31379937
41 HSF4 NM_001040667.3(HSF4):c.741G>A (p.Glu247=)SNV Uncertain significance 320186 rs373435397 16:67201389-67201389 16:67167486-67167486
42 MMAA NM_172250.3(MMAA):c.304G>A (p.Ala102Thr)SNV Uncertain significance 523564 rs1328584680 4:146560595-146560595 4:145639443-145639443
43 EPM2A NM_005670.4(EPM2A):c.*1691G>ASNV Uncertain significance 523391 rs750320097 6:145946861-145946861 6:145625725-145625725
44 MIP NM_012064.4(MIP):c.*132deldeletion Uncertain significance 309882 rs886049691 12:56844932-56844932 12:56451148-56451148
45 MIP NM_012064.4(MIP):c.493G>A (p.Gly165Ser)SNV Uncertain significance 309884 rs886049692 12:56847407-56847407 12:56453623-56453623
46 MIP NM_012064.4(MIP):c.361-10C>TSNV Uncertain significance 309886 rs886049693 12:56847549-56847549 12:56453765-56453765
47 MIP NM_012064.4(MIP):c.98G>A (p.Arg33His)SNV Uncertain significance 309887 rs139963297 12:56848300-56848300 12:56454516-56454516
48 HSF4 NM_018378.3(FBXL8):c.896A>G (p.Tyr299Cys)SNV Uncertain significance 320166 rs777343855 16:67197494-67197494 16:67163591-67163591
49 HSF4 NM_001040667.3(HSF4):c.-191C>GSNV Uncertain significance 320174 rs769427775 16:67198524-67198524 16:67164621-67164621
50 HSF4 NM_001040667.3(HSF4):c.1137G>A (p.Pro379=)SNV Uncertain significance 320189 rs369862977 16:67202788-67202788 16:67168885-67168885

Copy number variations for Cataract from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 86882 14 67000000 106368585 Copy number cataract
2 89231 15 17000000 100338915 Copy number cataract
3 106728 17 1 11200000 Copy number cataract
Sources

Expression for Cataract

About this section
Search GEO for disease gene expression data for Cataract.
Sources

Pathways for Cataract

About this section

Pathways related to Cataract according to KEGG:

36
# Name Kegg Source Accession
1 Protein processing in endoplasmic reticulum hsa04141
Sources

GO Terms for Cataract

About this section

Cellular components related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gap junction GO:0005921 8.96 GJA8 GJA3
2 connexin complex GO:0005922 8.62 GJA8 GJA3

Biological processes related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.56 RHO GJA3 CRYGS CRYGD CRYGC CRYBB3
2 lens development in camera-type eye GO:0002088 9.17 LIM2 GJA8 CRYGS CRYGD CRYGC CRYBB3
3 gap junction-mediated intercellular transport GO:1990349 9.16 GJA8 GJA3

Molecular functions related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of eye lens GO:0005212 9.17 LIM2 CRYGS CRYGD CRYGC CRYBB3 CRYBA1
Sources

Sources for Cataract

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....